---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-036822"
form_type: "8-K"
ticker: "RAPP"
cik: "0002012593"
company_name: "Rapport Therapeutics, Inc."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-25T00:13:22.011718+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rapport Therapeutics FY2024 net loss $78.3M; RAP-219 epilepsy trial top line Q3 2025

## Summary
- Net loss $78.3M for FY2024 vs $34.8M in FY2023; R&D expense $60.9M up from $28.0M.
- Phase 2a trial of RAP-219 in refractory focal epilepsy topline results expected Q3 2025 (narrowed timeline).
- Appointed Jeffrey Sevigny, M.D., as chief medical officer, effective immediately.
- Cash and investments $305.3M at year-end; expected to fund operations through end of 2026.
- FDA placed IND for Phase 2a DPNP trial on clinical hold; company finalizing trial plans.

## SEC filing metadata
- accession: 0000950170-25-036822
- form_type: 8-K
- ticker: RAPP
- cik: 0002012593
- company_name: Rapport Therapeutics, Inc.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2012593/000095017025036822/0000950170-25-036822-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2012593/000095017025036822/rapp-20250311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-036822
- JSON: https://secwatch.observer/filing/0000950170-25-036822.json
- Plain text: https://secwatch.observer/filing/0000950170-25-036822.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.